Andrea L. Casillas
YOU?
Author Swipe
View article: Figure S2 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S2 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Fig S2
View article: Figure S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Fig S3
View article: Table S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 1
View article: Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 3
View article: Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Fig S1
View article: Table S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 4
View article: Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Fig S4
View article: Data from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Data from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Immune checkpoint inhibitors (ICI) have changed the treatment paradigm for many cancers but have not shown benefit in prostate cancer. Chronic inflammation contributes to the immunosuppressive prostate tumor microenvironment and is associa…
View article: Table S2 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S2 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 2
View article: Table S5 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S5 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy Open
Supplemental table 5
View article: Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy
Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy Open
Immunotherapy has changed the treatment paradigm for many types of cancer, but immune checkpoint inhibitors (ICIs) have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to the immunosuppressive prostate tumor mi…
View article: PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer
PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer Open
Lipid droplets (LDs) are dynamic organelles with a neutral lipid core surrounded by a phospholipid monolayer. Solid tumors exhibit LD accumulation, and it is believed that LDs promote cell survival by providing an energy source during ener…
View article: PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer Open
PIM kinases have important pro-tumorigenic roles and mediate several oncogenic traits, including cell proliferation, survival, and chemotherapeutic resistance. As a result, multiple PIM inhibitors have been pursued as investigational new d…
View article: PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion
PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion Open
Distinguishing key factors that drive the switch from indolent to invasive disease will make a significant impact on guiding the treatment of prostate cancer (PCa) patients. Here, we identify a novel signaling pathway linking hypoxia and P…
View article: Figure S6 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S6 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Loss of PIM blunts hypoxia-induced stabilization of HIF-1/2 and the expression of HIF-1 target genes
View article: Figure S1 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S1 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Treatment with anti-angiogenic agents increases CAIX expression
View article: Figure S2 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S2 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
PIM1 expressing tumors maintain vasculature during treatment with anti-angiogenic agents
View article: Data from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Data from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Purpose: Patients develop resistance to antiangiogenic drugs, secondary to changes in the tumor microenvironment, including hypoxia. PIM kinases are prosurvival kinases and their expression increases in hypoxia. The goal of this stu…
View article: Figure S4 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S4 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Combinatorial inhibition of PIM and VEGF produces synergistic anti-tumor activity in xenograft models of prostate and colon cancer
View article: Figure S7 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S7 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Simultaneous inhibition of PIM and VEGF reduces colon cancer metastasis
View article: Figure S4 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S4 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Combinatorial inhibition of PIM and VEGF produces synergistic anti-tumor activity in xenograft models of prostate and colon cancer
View article: Figure S2 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S2 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
PIM1 expressing tumors maintain vasculature during treatment with anti-angiogenic agents
View article: Figure S1 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S1 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Treatment with anti-angiogenic agents increases CAIX expression
View article: Figure legends from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure legends from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Supplemental Figure legends
View article: Figure legends from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure legends from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Supplemental Figure legends
View article: Figure S8 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S8 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Metastases arising from prostate tumors show significant regions of hypoxia
View article: Figure S8 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S8 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Metastases arising from prostate tumors show significant regions of hypoxia
View article: Figure S5 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S5 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
PIM inhibition blunts the expression of HIF-1 target genes in hypoxia
View article: Figure S5 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S5 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
PIM inhibition blunts the expression of HIF-1 target genes in hypoxia
View article: Figure S3 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Figure S3 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents Open
Dose response curves for bevacizumab